TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02493140

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cashew apple extract (Cashewin)
Description: 6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner, each capsule containing 200 mg of Cashewin) during 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner) during 12 weeks
Study: NCT01468883

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: M
Description: Modified radical mastectomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: X
Description: Excisional biopsy plus radiation
Study: NCT03750617

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pre-endoscopic screening risk assessment
Description: pre-endoscopic screening risk assessment
Study: NCT01887665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incentives
Description: A structured system of prize-based financial incentives rewards attendance at treatment visits.
Study: NCT00654017

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo comparator to be given per protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: oral sildenafil citrate at an initial dose of 25 mg, which could have been up-titrated to 50 mg at Visit 3 based on the patient's efficacy, safety and tolerability responses; at Visits 4 and 5, the dose could remain the same, be increased to 100 mg, or decreased to 25 mg depending on the safety, efficacy, and tolerability
Study: NCT00667875

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Naltrexone (25mg or 50 mg per titration schedule)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone + Aripiprazole
Description: Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)
Study: NCT05600452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat acclimation
Description: Repeated heat exposures with light exercise sufficient to elevate deep body temperature to \~ 38.5C

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heat acclimation
Description: Repeated heat exposures with light exercise sufficient to elevate deep body temperature to \~ 38.5C
Study: NCT03824730

Intervention type: DEVICE
Intervention: Stenting of the Common and/or External Iliac Arteries
Description: Stenting of the Common and/or External Iliac Arteries was performed in the angiographic suite. Under local anesthesia, arterial access was obtained through standard percutaneous puncture of the common femoral artery, brachial approach, or simultaneous brachial and femoral approach.~Iliac lesion crossing was achieved through intraluminal or subintimal manner depending on the behavior of the lesion intraoperatively.~Predilatation of the occlusion before stent deployment was performed at the discretion of the operator.~Balloon-expandable stents were used for proximal, ostial lesions, whereas self-expanding stents were deployed in all other lesions.~Both stents were used in long lesions involving heavily calcified common iliac arteries.
Study: NCT01576107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise counseling (behavior change techniques)
Description: 4-week exercise intervention for cancer patients of different entities and out-patient regimes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress-management training
Description: 4-week stress-management-training for cancer patients of different entities and out-patient regimes.
Study: NCT02622984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RBIRT
Description: Intervention group will receive the telehealth or remote behavior intervention and referral for substance use (RBIRT). Other group will receive treatment as usual which is SBIRT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SBIRT
Description: Face to face standard intervention considered treatment as usual.
Study: NCT03429972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elasto-Gel™
Description: Elasto-Gel™ hypothermia mitts and slippers contain glycerine, which has thermal properties, allowing use for cold therapies.

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 80mg/m\^2 of Paclitaxel is administered by infusion for 60 mins once a week, for a total of 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m\^2 of Paclitaxel is administered by infusion for 60 mins once a week, for a total of 12 cycles
Study: NCT01771731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis
Study: NCT01747486

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR zeta and 4-1BB costimulatory domains)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR zeta and 4-1BB costimulatory domains)
Study: NCT01877343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CVInsight(TM)
Description: Patient will be placed on a tilt table and pulse oximetry (Nonin Medical) and blood pressure will be measured at different table positions (different angles). Four positions will be explored. A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
Study: NCT01726842

Intervention type: DEVICE
Intervention: Pediatric Vision Scanner
Description: Subject is scanned with a 2.5 second pediatric vision scanner device test.

Intervention type: DEVICE
Intervention: Pediatric Vision Scanner
Description: Subject is scanned with a 2.5 second pediatric vision scanner device test.

Intervention type: DEVICE
Intervention: Pediatric Vision Scanner
Description: Subject is scanned with a 2.5 second pediatric vision scanner device test.
Study: NCT01347892

Intervention type: OTHER
Intervention: DeNovo NT Natural Tissue Graft
Description: DeNovo NT is a juvenile cartilagenous tissue graft, inclusive of a viable human cartilage cells. It is provided as particulated tissue pieces of approximately 1mm3 each
Study: NCT03335579

Intervention type: COMBINATION_PRODUCT
Intervention: inhalation or propofol ,epidural or general anesthesia, remifentanil or sufentanil
Description: Different combination of opioids and anesthetics

Intervention type: COMBINATION_PRODUCT
Intervention: inhalation or propofol ,epidural or general anesthesia, remifentanil or sufentanil
Description: Different combination of opioids and anesthetics
Study: NCT01500018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single oral dose of 100 mg
Study: NCT00511446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, oxaliplatin, capecitabine
Description: Docetaxel: 35 mg/m2, IV day 1, 8 of each 21 day cycle; Oxaliplatin: 70 mg/m2, IV day 1, 8 of each 21 day cycle; Capecitabine: 2x800 mg/m2 PO IV day 1 evening till morning of day 15 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT03777488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 1 gram intravenously
Description: Intravenous tranexamic acid crossover to oral and intramuscular arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 1 gram intravenously
Description: Intravenous tranexamic acid crossover to oral and intramuscular arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 1 gram intravenously
Description: Intravenous tranexamic acid crossover to oral and intramuscular arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 1 gram intravenously
Description: Intravenous tranexamic acid crossover to oral and intramuscular arms
Study: NCT03655236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: low dose, orally, once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: high dose, orally, once-daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, orally, once-daily
Study: NCT02055443

Intervention type: OTHER
Intervention: 12-lead holter monitor application
Description: -- The study coordinator will then obtain a 5-minute baseline high resolution (1000 samples/second), 12-lead resting ECG stream using H12+ holter ECG machine (Mortara Instruments, Milwaukee, WI). This ECG will be performed before the subject completed their clinical stress test.~* The patient will then complete the scheduled nuclear stress test that involves exercise treadmill testing followed by single-photon emission computerized tomography (SPECT) scan as per hospital protocols. The exercise treadmill test and SPECT nuclear imaging scan are clinical in nature, and therefore, separate from the research study.~* After completing the scheduled exam, the study coordinator will obtain another 5-minute 12-lead ECG stream prior to removing the chest electrodes but before their nuclear scan.
Study: NCT02546843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium
Description: cisatracurium 0.15mg/kg intravenously
Study: NCT01500018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single oral dose of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single oral dose of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single oral dose of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single oral dose of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single oral dose of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single oral dose of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single oral dose of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 45 mg
Study: NCT03777488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 1 gram intravenously
Description: Intravenous tranexamic acid crossover to oral and intramuscular arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 1 gram intravenously
Description: Intravenous tranexamic acid crossover to oral and intramuscular arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 2 grams oral solution
Description: Oral tranexamic acid crossover to intravenous and intramuscular arms
Study: NCT01500018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 45 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 45 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 45 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 45 mg
Study: NCT02546843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nonspecific Neuromuscular Blockade reversal
Description: neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Specific Neuromuscular Blockade reversal
Description: Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maintaining the depth of neuromuscular blockade - rocuronium
Description: repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maintaining the depth of neuromuscular blockade - cisatracurium
Description: repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1
Study: NCT06196021

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular hyaluronic acid injection
Description: Hyaluronic acid was injected into the symptomatic knees of the patients a total of 3 times, once a week for 3 weeks.~Injections were administered by the physician using a lateral approach with the patient lying on his back and the knee in full extension.~After each injection, patients were warned to apply cold to avoid possible local reactions and not to overload for 24 hours.~Hyaluronic acid preparation was in the form of 2.5 ml solutions obtained biotechnologically, containing 10 mg sodium hyaluronan in each milliliter.~The hyaluronan in solution was of medium molecular weight (0.9 million daltons) but still lower molecular weight than the hyaluronan in normal healthy synovial fluid.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular hyaluronic acid injection
Description: Hyaluronic acid was injected into the symptomatic knees of the patients a total of 3 times, once a week for 3 weeks.~Injections were administered by the physician using a lateral approach with the patient lying on his back and the knee in full extension.~After each injection, patients were warned to apply cold to avoid possible local reactions and not to overload for 24 hours.~Hyaluronic acid preparation was in the form of 2.5 ml solutions obtained biotechnologically, containing 10 mg sodium hyaluronan in each milliliter.~The hyaluronan in solution was of medium molecular weight (0.9 million daltons) but still lower molecular weight than the hyaluronan in normal healthy synovial fluid.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intra-articular hyaluronic acid injection
Description: Hyaluronic acid was injected into the symptomatic knees of the patients a total of 3 times, once a week for 3 weeks.~Injections were administered by the physician using a lateral approach with the patient lying on his back and the knee in full extension.~After each injection, patients were warned to apply cold to avoid possible local reactions and not to overload for 24 hours.~Hyaluronic acid preparation was in the form of 2.5 ml solutions obtained biotechnologically, containing 10 mg sodium hyaluronan in each milliliter.~The hyaluronan in solution was of medium molecular weight (0.9 million daltons) but still lower molecular weight than the hyaluronan in normal healthy synovial fluid.
Study: NCT04729647

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mastectomy
Description: Mastectomy for breast cancer Blood sample for Complete Blood Cell Count and other blood parameters (Delta Neutrophil Index, Immature Granulocyte Count)
Study: NCT04732364

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound guided erector spinae plan block using bupivacaine for modified radical mastectomy
Description: Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided erector spinae plan block with bupivacaine and Dexmetonidine for modified radical mastectomy
Description: Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided erector spinae plan block with bupivacaine and magnesium slphate for modified radical mastectomy
Description: Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
Study: NCT01064323

Intervention type: DEVICE
Group type: OTHER
Intervention: Intermittent pneumatic compression of the lower extremities
Description: IPC will be done for 3 divided hours daily for 4 weeks
Study: NCT04254835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein
Description: Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein
Description: Conventional Fluoride varnish
Study: NCT02598258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sauna and cold water bath
Description: Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after, subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
Study: NCT03777488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 2 grams oral solution
Description: Oral tranexamic acid crossover to intravenous and intramuscular arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 2 grams oral solution
Description: Oral tranexamic acid crossover to intravenous and intramuscular arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 2 grams oral solution
Description: Oral tranexamic acid crossover to intravenous and intramuscular arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 2 grams oral solution
Description: Oral tranexamic acid crossover to intravenous and intramuscular arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 2 grams oral solution
Description: Oral tranexamic acid crossover to intravenous and intramuscular arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 1 gram intramuscular
Description: Intramuscular tranexamic acid crossover to oral and intravenous arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 1 gram intramuscular
Description: Intramuscular tranexamic acid crossover to oral and intravenous arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 1 gram intramuscular
Description: Intramuscular tranexamic acid crossover to oral and intravenous arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 1 gram intramuscular
Description: Intramuscular tranexamic acid crossover to oral and intravenous arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 1 gram intramuscular
Description: Intramuscular tranexamic acid crossover to oral and intravenous arms
Study: NCT01500018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 45 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 45 mg
Study: NCT03777488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 1 gram intramuscular
Description: Intramuscular tranexamic acid crossover to oral and intravenous arms
Study: NCT02820116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: In the neoadjuvant treatment phase, eligible patients will receive 125mg of Icotinib three times per day for 8 weeks (56 days). In the post-surgery phase, Icotinib 125mg/three tims/day taken orally for 2 years or till disease progression or unacceptable toxicity.
Study: NCT01300650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra 100 mg subcutaneous injection daily
Study: NCT01500018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 45 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 45 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 45 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 8 mg
Study: NCT02944032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CogmedRM
Description: Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. Difficulty of the tasks is automatically adjusted on a trial-by-trial basis throughout each training session to match a child's current working memory span, such that as the child becomes more proficient, the exercises become more difficult. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.